overall survival
FIG 2. · Panel A
Panel A 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Howard Colman, Giuseppe Lombardi, Eric T Wong, Tobias Walbert, Marica Eoli, Andrew B Lassman, David M Peereboom, Sani H Kizilbash, Carlos Kamiya-Matsuoka, Marshall W Pitz, Roy E Strowd, Annick Desjardins, Priya Kumthekar, Warren Mason, Alessia Pellerino, Riccardo Soffietti, Nicholas Butowski, Peter A Forsyth, Mohamed A Hamza, Peter Hau, Enrico Lallana, Burt Nabors, David Piccioni, Erik J Uhlmann, Liam C Welsh, Patrick Y Wen, Jorg Dietrich, Chao Wang, Victor A Levin
J Clin Oncol 44(8) 641-652
PURPOSE: STELLAR (ClinicalTrials.gov identifier: NCT02796261) was a phase III, randomized, open-label trial of eflornithine + lomustine versus lomustine monotherapy in patients with recurrent grade 3 astrocytoma. METHODS: At trial initiation, eligibility criteria included: age ≥18 years, anaplastic astrocytoma (2016 WHO CNS Tumor classification [WHO CNS4]), first recurrence ≥6 months after radiation and temozolomide (TMZ), Karnofsky performance status ≥70, and no imaging findings consistent with grade 4 glioblastoma. Random assignment (1:1) was stratified by isocitrate dehydrogenase (IDH) mutation, age, resection extent, and geography. Patients received eflornithine (2.8 g/m2 orally, every 8 hours [2 weeks on, 1 week off]) + lomustine (90 mg/m2 orally, once every 6 weeks), or lomustine monotherapy (110 mg/m2 once every 6 weeks). The primary end point was overall survival (OS). RESULTS: Among 343 patients randomly assigned across 74 sites in eight countries, there was no difference in survival between eflornithine + lomustine and lomustine monotherapy (median OS 23.4 v 20.3 months, hazard ratio [HR], 0.94). Following changes in classification and grading in the 2021 WHO CNS5, a subset analysis of patients with IDH-mutant, grade 3 astrocytoma (n = 196), defined in 2024, before unblinding, showed clinically meaningful improvements in median OS with eflornithine + lomustine versus lomustine monotherapy (34.9 v 23.5 months, HR, 0.64) and median progression-free survival (PFS, 15.8 v 7.2 months, HR, 0.57). No differences were observed among patients with CNS grade 4 disease. Grade ≥3 treatment-emergent adverse events of relevance were related to reversible myelosuppression (eflornithine + lomustine 42% v lomustine monotherapy 29% of patients) and hearing impairment (24% v 0%). No new safety signals were identified. CONCLUSION: Clinically meaningful improvements were observed; eflornithine + lomustine doubled PFS and improved OS in patients with recurrent IDH-mutant, grade 3 astrocytoma, but not grade 4 tumors, after prior radiotherapy and TMZ, consistent with its cytostatic mechanism of action.
2 个 Figure · 4 个 KM 面板
FIG 2. Kaplan-Meier curves of OS for the (A) ITT population and (B) IDH -mut grade 3 subset (investigator assessment by treatment). P values are from the log-rank test stratified by age (≤45 v > 45) and number of prior surgeries. For the ITT population P value was also stratified by IDH status (mutant v wild-type). CDKN2A/B , cyclin-dependent kinase inhibitor 2A/B ; IDH -mut, isocitrate dehydrogenase mutation; ITT, intention-to-treat; N, total number of patients; OS, overall survival.
FIG 3. Kaplan-Meier curves of PFS for the (A) ITT population and (B) IDH -mut grade 3 subset (investigator assessment by treatment). P values are from the log-rank test stratified by age (≤45 v > 45) and number of prior surgeries. For the ITT population P value was also stratified by IDH status (mutant v wild-type). CDKN2A/B , cyclin-dependent kinase inhibitor 2A/B ; IDH -mut, isocitrate dehydrogenase mutation; ITT, intention-to-treat; N, total number of patients; PFS, progression-free survival.
这些图片未产生 KM 曲线结果,不在主页面重复展示。